CD8 super(+) T cells Reactive to Survivin Antigen in Patients with Multiple Myeloma

• Published in: Clinical cancer research Vol. 13; no. 3; pp. 1053 - 1060
• Main Authors: Grube, Matthias, Moritz, Stephanie, Obermann, Ellen C, Rezvani, Katayoun, Mackensen, Andreas, Andreesen, Reinhard, Holler, Ernst
• Format: Journal Article
• Language: English
• Published: 01.02.2007
• ISSN: 1078-0432

PURPOSE: Survivin is a member of the inhibitors of apoptosis family and is overexpressed in different types of malignancies. Cytotoxic T cells recognizing survivin epitopes can be elicited in vitro and by vaccination in patients with leukemia, breast cancer, and melanoma. We did this study to investigate whether survivin-specific CD8 super(+) T cells occur in patients with multiple myeloma. Experimental Design: An HLA-A2.1-binding survivin peptide was used to detect peptide-specific T cells by a quantitative real-time PCR to measure antigen-specific IFN- gamma mRNA expression in 23 patients with myeloma and 21 healthy volunteers. T cells producing IFN- gamma in response to survivin were further analyzed for expression of CD45RA and CCR7 to determine phenotypic characterization. Additional immunohistochemical analyses of survivin antigen expression in bone marrow specimens of patients was done. RESULTS: T cells recognizing HLA-A2.1-binding survivin peptide were detected in 9 of 23 patients and in 1 of 21 healthy volunteers. Survivin-reactive T cells were identified as terminally differentiated effector T cells (CD8 super(+), CD45RA super(+), and CCR7 super(-)). Positive survivin expression of myeloma cells in bone marrow specimens was shown in 7 of 11 patients. CONCLUSION: We provide, for the first time, evidence of T cell reactivity against survivin antigen in patients with multiple myeloma. Our data suggest the immunogenicity of survivin antigen in multiple myeloma and that immunotherapeutic strategies using survivin as a target antigen might be an option for patients with this disease.